Pharmacy Times September 16, 2024
For biosimilars to overcome these entrenched market dynamics, they must not only compete on price but actively work to build a network of support among providers and patients.
Given the high cost of biologic drugs when the first biosimilars—highly similar, lower-cost alternatives—began to be developed, expectations for their cost-saving potential were high. Unfortunately, in the near decade since the first biosimilar was approved of filgrastim-sndz (Zarxio; Sandoz) in 2015,1 this promise has failed to materialize.
When it comes to the cost-impact of biologics, Humira (adalimumab), manufactured by AbbVie, is the perfect poster child. Initially approved to treat moderate-to-severe rheumatoid arthritis in adults, the drug went on to receive expanded indications for several other autoimmune conditions. That, combined with its exorbitant...
Today's Sponsors
Today's Sponsor